Autologous peripheral blood stem cell transplantation following myeloablative chemotherapy is being increasingly utilized in the treatment of a variety of malignancies. We administered busulfan 16 mg/kg orally, thiotepa 500-700 mg/m 2 i.v., and carboplatin 800-1000 mg/m 2 i.v. to 56 women with metastatic carcinoma of the breast. Autologous peripheral blood stem cells, which had been collected after a combination of chemotherapy and granulocyte colony-stimulating factor, were infused on day 0. The major toxicities of the conditioning regimen included severe pancytopenia, stomatitis, nausea, emesis, diarrhea, fever, and infection. Transplant-related mortality was 1.8%. The incidence of opportunistic viral infections was 42.9%. Fourteen individuals achieved a complete response. The actuarial survival at 1223 days was 13.7% for the entire group of patients; the actuarial survival at 1009 days was 39.3% among complete responders. The functional status of the immune system was determined following transplantation in a subset of patients. Peripheral blood mononuclear cells were obtained before and after stem cell infusion, and were analyzed phenotypically and functionally. Proliferative and interleukin-2 synthetic ability of these cells was assessed following stimulation with phytohemagglutinin and anti-CD3 antibody. The response to influenza peptides was also ascertained. Proliferative and interleukin-2 synthetic capacity was markedly impaired for over a year. Memory response was virtually absent for up to 2 years following transplantation. The prolonged and marked immunosuppression following this myeloablative regimen was associated with a high incidence of opportunistic viral infections, and may have contributed to disease relapse and progression especially in patients who failed to achieve a complete response following transplantation. Keywords: myeloablative chemotherapy; breast cancer; stem cell transplant; immunosuppression Autologous peripheral blood stem cell transplantation (PBSCT) has emerged as a credible therapeutic modality in the treatment of recurrent and high-risk malignancies. [1] [2] [3] [4] Although this form of treatment has been most successful in hematologic malignancies, some therapeutic gains have also been achieved in solid tumors, including carcinoma of the breast.
the treatment of recurrent and high-risk malignancies. [1] [2] [3] [4] Although this form of treatment has been most successful in hematologic malignancies, some therapeutic gains have also been achieved in solid tumors, including carcinoma of the breast. [5] [6] [7] Myeloablative doses of chemotherapy usually result in a prolonged period of immunologic compromise. In prior studies, it has been demonstrated that although profound and prolonged immunosuppression is a feature of all types of bone marrow transplantation (BMT), the depth and duration of immunosuppression is greatest following allogeneic BMT, intermediate after syngeneic BMT, and least following autologous BMT. 8, 9 It also appears that the use of autologous PBSCT rather than autologous BMT leads to faster hematopoietic and immunologic reconstitution. 10 The implications of these findings are important and would favor a lower incidence of opportunistic infections and, conceivably, relapse of the underlying malignancy following autologous PBSCT. 10 We utilized a novel, highly myeloablative conditioning chemotherapy regimen followed by autologous PBSCT in 56 women with metastatic carcinoma of the breast. Response rates and survival status were determined as was the incidence of opportunistic viral infections following transplantation. The degree of immunosuppression and the kinetics of immunologic reconstitution after transplantation were studied in an attempt to correlate immune recovery with clinical outcome parameters.
Materials and methods

Patients
Fifty-six women with metastatic breast carcinoma underwent autologous PBSCT between June, 1994 and April 1996 at the University of Connecticut Health Center. The initial phase of treatment consisted of two (20 patients) or three (36 patients) courses of dose-intense chemotherapy (etoposide 60 mg/kg intravenously; cyclophosphamide 3 g/m 2 intravenously; and paclitaxel 200 mg/m 2 intravenously) administered for the dual purpose of stem cell procurement and tumor cytoreduction. The goal was to obtain 5 × 10 6 CD34-positive cells/kg body weight following the second such course of chemotherapy. One month after the final course of this chemotherapy, a myeloablative conditioning regimen consisting of busulfan 4 mg/kg/day (day −10 to day −7) orally, thiotepa 125-175 mg/m 2 /day (day −6 to day −3) intravenously, and carboplatin 200-250 mg/m 2 /day (day −6 to day −3) intravenously was administered followed by autologous stem cell infusion (day 0). Toxicity was evaluated in accordance with the World Health Organization criteria. 11 All individuals who were sero-positive for herpes simplex virus (HSV) received acyclovir, 400 mg orally twice daily, from the initiation of conditioning chemotherapy until 50 days following stem cell infusion.
Disease status was reassessed 60 days following stem cell infusion by computerized axial tomography of the chest, abdomen, and pelvis as well as by total body bone scan. An immunocytochemical staining assay (BIS Laboratories, Reseda, CA, USA) was utilized to detect micrometastases in the bone marrow and in the peripheral blood stem cell (PBSC) product obtained after the first and second cycles of stem cell mobilizing chemotherapy. Only PBSC products with a negative immunocytochemical assay were utilized for stem cell rescue. Complete response (CR) was defined as the absence of clinical and radiologic evidence of disease. Partial response (PR) and non-response (NR) were described, respectively, as greater than or less than 50% reduction in the size of measurable disease. Progression was indicated by worsening disease.
Restaging studies were repeated every 3 to 6 months. The incidence of opportunistic viral infections within the first year following autologous PBSCT was ascertained by reviewing the charts of all patients. A diagnosis of varicella-zoster virus (VZV) infection was confirmed by direct fluorescent antibody testing (Merifluor VZV; Meridian Diagnostics, Cincinnati, OH, USA). Cytomegalovirus (CMV) infection or excretion was detected by the identification of immediate early and early antigens in various body fluids (Chemicon International, Temecula, CA, USA). In addition, VZV, CMV, HSV and adenovirus infections were confirmed by culture. Ten patients agreed to participate in the immunologic study. A total of 5 to 7 ml of heparinized peripheral blood was collected after obtaining informed consent from these 10 patients prior to HDC, and subsequently, at various time intervals up to 2 years after stem cell infusion. Peripheral blood was also obtained from six normal individuals, and from five patients with melanoma and five patients with breast cancer treated with other therapeutic modalities.
Culture medium
Iscove's modified Dulbecco's medium (IMDM; Life Technologies, Grand Island, NY, USA) containing 5 mm each of l-asparagine, l-glutamine and l-arginine supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, NY, USA) and 10 mg/ml of gentamicin (ElkinsSinn, Cherry Hill, NJ, USA) was utilized for all in vitro experiments. Henceforth, this culture medium is referred to as complete medium (CM).
Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation using Ficoll-Hypaque (Sigma Chemicals, St Louis, MO, USA). The total number of viable cells was ascertained. Freshly isolated cells were used for phenotypic and functional analyses.
Monoclonal and polyclonal antibodies
Monoclonal antibodies against CD1a, CD3, CD4, CD8, CD34, MO1, B1, and polyclonal antibodies against mouse IgG and goat anti-mouse IgG-FITC (fluorescein isothiocyanate) were purchased from Coulter-Immunotech (Miami, FL, USA). Antibodies against T cell receptor (TCR) were also purchased from Coulter-Immunotech.
Phenotypic analysis
Mononuclear cells were isolated and washed three times with phosphate-buffered saline (PBS). A total of 2-4 × 10 5 cells were labeled with FITC-conjugated monoclonal antibodies and with control antibody at 4°C for 30 min. Subsequently, the cells were washed twice with cold PBS and resuspended in 0.5 ml of fixative buffer. Fluorescence-positive cells were counted in a fluorescence-activated cell sorter (FACS; Becton Dickinson, Franklin Lakes, NJ, USA) using Cell Quest software.
Proliferation of PBMC
Ficoll-Hypaque-isolated PBMC were washed four times with PBS and resuspended in CM. These cells (2 × 10 5 per well) were cultured in triplicate in 96-well U-bottomed plates (Costar, Cambridge, MA, USA) with phytohemagglutinin (PHA; Sigma Chemical Company) 2 g/ml or with anti-CD3 antibody (Coulter) 40 g/well for 5 days in the presence or absence of 50 U/ml of interleukin-2 (IL-2; Gibco-BRL, Gaithersburg, MD, USA). Radioactive thymidine 3 HTdR (Nen, Boston, MA, USA) 1 Ci/well was added to the wells for the last 16 h of culture. Cells were harvested in a Titertek semi-automatic cell harvester (Skatron, Sterling, VA, USA) and thymidine incorporation was measured in a Beckman liquid scintillation counter (Beckman Instruments, Irvine, CA, USA).
Interleukin-2 secretion by PBMC after stimulation
Peripheral blood mononuclear cells obtained from study patients and normal individuals were treated with PHA or anti-CD3 antibody as described above and supernatants of these cultures were removed after 24, 48, and 72 h of stimulation. The presence of IL-2 in the supernatant was measured using IL-2 ELISA kits (Endogen, Woburn, MA, USA) in accordance with the manufacturer's directions.
Memory response
Memory response was analyzed utilizing influenza peptides (CTELKLSDY for HLA-A1 and GILGFVFTL for HLA-A2) for patients and control subjects who were HLA-A1 and/or HLA-A2 positive. 12, 13 The presence of memory was determined by the ability of PBMC to elaborate interferongamma upon presentation of the peptides by autologous antigen presenting cells in vitro. Therefore, peripheral blood mononuclear cells (1 × 10 5 ) were stimulated with respective autologous or allogeneic HLA-A1 or -A2 matched antigen presenting cells (1 × 10 5 ) and pulsed with influenza peptides in microtiter plates for 24 h in tissue culture medium. Either monocyte lineage cells which had been derived from PBMC and cultured in granulocyte-macrophage colony-stimulating factor (GM-CSF, 1000 U/ml) as well as interleukin-4 (IL-4, 1000 U/ml) or allogeneic Epstein-Barr virus (EBV)-transformed B cells were used to present the influenza peptides. Antigen presenting cells were pulsed with 1 g/ml of the appropriate peptide/million cells in PBS for 2 h and irradiated with 100 Gy from a CS-137 source. Peripheral blood mononuclear cells obtained from patients and normal individuals were then stimulated with the antigen presenting cells in 96-well microculture plates (PBMC: antigen presenting cells = 10:1) in CM. After 24 h of culture, supernatants from all of the different wells were collected in duplicate and the presence of interferon-gamma was quantified using ELISA kits (Immunotech, Miami, FL, USA) in accordance with the manufacturer's directions.
Results
Clinical outcome: safety, toxicity and efficacy
The clinical characteristics of all 56 patients and their response status following autologous PBSCT are outlined in Table 1 . Seventy-one percent of these 56 patients had received radiation therapy several months or years prior to PBSCT. Ten patients agreed to participate in the immunologic study. Their clinical features were similar to those of the entire cohort of patients. The median age of these 10 patients was 48 years and they had received a median of two and nine prior chemotherapy regimens and cycles, respectively. The median interval from diagnosis of breast cancer to PBSCT and diagnosis of metastases to PBSCT was 25 months and 9 months, respectively. A median of two organ systems were involved with metastatic disease. Seven individuals had received radiation therapy prior to PBSCT. However, only two patients had been irradiated within 6 months of stem cell infusion. Therefore, it is unlikely that radiation therapy made any significant impact on the immunologic aspects of this study. The number of complete responders at 2 months following transplantation was 14 patients (25%). The overall response rate (complete and partial response) was 53.6%. The actuarial survival of the entire group of patients at 1223 days was 13.7% ( Figure 1) . However, the actuarial survival of the group of patients in complete remission following transplantation at 1009 days was 39.3% ( Figure 2 ). Major toxicities of the myeloablative regimen included grade 4 granulocytopenia and thrombocytopenia, grade 3 alopecia, grade 1-3 diarrhea, grade 1-3 nausea/vomiting, and grade 3-4 stomatitis. Eighty-eight percent of patients developed a grade 1-3 cutaneous auto-aggression syndrome which resembled cutaneous graft-versus-host disease. This erythematous, maculo-papular, desquamative eruption affected not only the palms and soles but also the intertriginous regions. It was likely not related to thiotepa toxicity because its median day of onset (day +11 following PBSCT ) occurred nearly 2 weeks after the completion of thiotepa therapy. Furthermore, the rash lasted for a median of 6 weeks and affected individuals required topical and systemic corticosteroids for relief of symptoms. Fifty patients (89.3%) developed a fever greater than 38°C when neutropenic and bacteremia was documented in 19 patients (33.9%). There was one treatment-related death from veno-occlusive disease of the liver. There were 29 documented instances of viral infection or excretion in 24 individuals (Table 2) . Cytomegalovirus disease in the form of gastritis was identified in one individual. Two other patients developed CMV viremia without disease. Additionally, CMV viruria alone was detected in four other patients. Twenty-four (83%) of these 29 viral infections occurred within 100 days of stem cell infusion. Figure 3 demonstrates the absolute number of PBMC/ml of blood obtained from healthy individuals (n = 6), from cancer patients (n = 10) and from transplant recipients (n = 10) before and after PBSCT. Immediately after transplantation, a burst of mononuclear cell growth was observed with some patients demonstrating a 10-fold increase in number as compared to control subjects. When these PBMC were characterized phenotypically (Table 3) , most of the cells were positive for both CD1a and MO1 markers indicative of precursor cells. Although the absolute number of these CD1a/MO1+ cells declined over the next 2 months, their number still remained relatively elevated until approximately 60 days following transplantation. The number of T lymphocytes including CD3 + , CD4
Immunological recovery
+ and CD8 + cells was reduced, with CD4 demonstrating the most profound suppression lasting to day 60 after stem cell infusion. Transplanted patients also exhibited a significant decrease in the number of CD3-positive lymphocytes as well as of T cell receptor ␣, ␤-or WT31-positive cells. Furthermore, the number of cells expressing the Fc receptor (CD16) was significantly reduced when compared to controls (data not shown). Table 4 describes the functional properties of PBMC obtained from transplanted patients at different time intervals. The mononuclear cells did not proliferate in response to PHA or anti-CD3 antibody, even in the presence of exogenous IL-2. Only a marginal proliferative response was observed when exogenous IL-2 was added, indicating an inability of such cells to respond to IL-2 even after stimulation. This was in marked contrast to the responses observed in normal individuals and non-transplanted cancer patients, where a significant amount of IL-2 was detected in the samples (Table 5 ). This severe functional deficit of the immune system continued to be demonstrated at 1 year following PBSCT. PBSCT = peripheral blood stem cell transplantation; PHA = phytohemagglutinin; IL-2 = interleukin-2.
Functional analysis of the recovering immune system
Table 5
Interleukin-2 secretion (pg/ml/2 × 
Memory response
Memory response was evaluated in a selected number of cases based on HLA-A1 or HLA-A2 phenotype because influenza matrix peptides restricted to these two MHC class 1 molecules are known.
12,13 A significant amount of interferon-gamma (100-200 pg/ml/2 × 10 5 cells) was detected in the culture supernatant when PBMC obtained from normal individuals were stimulated with the appropriate peptides. In contrast, PBMC obtained from transplanted patients failed to elaborate any interferon-gamma in the culture supernatants during the first 60 days following transplantation. Even at 2 years after transplantation, interferongamma production remained significantly impaired (Table 6) .
Discussion
Numerous studies have outlined the sequence of immunologic reconstitution following allogeneic, syngeneic and autologous BMT. [8] [9] [10] Both quantitative and qualitative Table 6 Memory response (interferon-␥ production) by PBMC when stimulated by influenza peptide
Source of PBMC Mean interferon-␥ levels pg/ml
Normal volunteers (n = 6) 160 Cancer patients (5) deficits of T lymphocytes, B lymphocytes and, to a lesser extent, natural killer (NK) cells exist for prolonged periods. 14 Fewer studies have been performed in the autologous PBSCT setting. The peripheral blood stem cell (PBSC) harvest product contains a normal number (compared to peripheral blood) of T lymphocyte subsets, B lymphocytes, NK cells, and CD25-expressing cells, as well as a normal CD4:CD8 ratio. 10, [15] [16] [17] Harvested T lymphocytes secrete IL-2 when stimulated by PHA, and exhibit lymphokine-activated killer (LAK) activity when incubated with IL-2. 15, 18, 19 Hematologic recovery is usually swift and complete following autologous PBSCT. Similarly, immunologic recovery is more rapid following autologous PBSCT compared to autologous and allogeneic BMT. [20] [21] [22] [23] Natural killer cells (NK cells) (CD3 − and CD56 + ) are among the earliest cells to recover numerically following autologous PBSCT 10 and exceed the normal value by 6 weeks before returning gradually to baseline. 16 The number of NK cells is significantly greater following autologous PBSCT compared to autologous BMT for up to 5 months after transplantation. 15, 20, 21 The absolute lymphocyte count recovers by 17 days following stem cell infusion 22 and CD3 + cells normalize quantitatively by 2-4 weeks. 16, 20 CD8 + cells recover numerically by 3 weeks whereas CD4
+ cells remain subnormal for 60 days or longer 10, 16, 20, 22 leading to a reversal of the CD4:CD8 ratio for 4 or more months. 16, 18, 20, 22 Cytotoxic T cells (CD8 + , CD11b − ) recover rapidly whereas suppressor T lymphocytes (CD8 + , CD11b + ) remain subnormal for a prolonged period. 16 Similarly, helper-inducer cells (CD4 + , CD45RO + ) and memory T lymphocytes (CD4 + , CD29 + ) recover rapidly while suppressor-inducer cells (CD4 + , CD45RA + ) remain subnormal for a prolonged period. 16, 20, 21 Recovery of activated CD3 + cells, CD25 + cells and T cell receptor gamma/delta-bearing lymphocytes is also faster following autologous PBSCT compared to autologous BMT. 16, 21 Re-establishment of immunologic function is also prompt following autologous PBSCT. Response of T lymphocytes to stimulation by IL-2 and the ability of these cells to secrete IL-2 in response to stimulation by PHA recovers within 30 days after autologous PBSCT. 15, 18, 21 Our findings are in marked contrast to the data reported in the literature. Although there was an initial burst of precursor cells, comprised mainly of CD1A + , MO1 + , CD3
− cells, the regeneration of T lymphocytes was markedly delayed with fewer than 30% of circulating cells being CD3 + by day +60 and less than 10% of circulating cells being CD4
+ at that time point. Even more dramatic was the virtual absence of T cell function with a severely impaired ability of T lymphocytes to proliferate or synthesize IL-2 in response to lectin or receptor-mediated stimulation lasting for over a year, and an undetectable memory response to influenza peptides for up to 2 years following autologous stem cell infusion. It is likely that the use of busulfan, a bi-functional alkylator that not only results in complete ablation of the bone marrow but also has a profound effect on all bone marrow-derived cells such as thymic dendritic cells, 24, 25 contributed significantly to the prolonged immunosuppression seen in our patients. One could speculate that complete ablation of the bone marrow requires a complete rebuilding of the immune system from the stem cell, not unlike the situation observed after allogeneic transplantation where the kinetics of immune recovery are similar to those seen in our patient population. 10 Conversely, destruction of the dendritic cells may severely impair the thymic microenvironment and with it the thymic function as well, leading to a delay in immune reconstitution until the thymic architecture has been rebuilt. 23, 26 The number of opportunistic viral infections identified following autologous PBSCT with our myeloablative regimen was significant. The majority of these infections occurred within the first 4 months, the period of maximum immunocompromise following autologous PBSCT. Although there was no mortality from opportunistic viral infections in this series, there was considerable morbidity and inconvenience to the patient because of the need for therapy and, occasionally, hospitalization. Certainly, the incidence, if not the severity, of such infections after our myeloablative regimen resembled the scenario after allogeneic BMT. It is likely that our chemotherapy was not only myeloablative but also extremely immunoablative. This would suggest that in the autologous PBSCT setting, the type of chemotherapy regimen may be responsible for the subsequent degree and duration of immunosuppression. 10 The high response rate achieved with our myeloablative regimen was gratifying. Unfortunately, few patients remained in remission for prolonged periods of time. Only the subset of patients in complete remission following transplantation were long-term survivors whereas none of the patients with residual disease after autologous PBSCT had prolonged survival. Although resistance of clones of malignant cells to chemotherapy is the most obvious explanation for such relapses and disease progression, it has been postulated that an inadequately functioning immune system may also contribute to early cases of relapse especially in patients who fail to achieve a complete remission following autologous PBSCT. 10 In fact, many of the relapses seen in our patients occurred early after transplantation during the period of maximal immunosuppression. Adoptive immunotherapy appears to work most effectively when there is minimal residual disease, 14 a status that is achieved in patients with breast cancer in clinical complete remission or near complete remission immediately after autologous PBSCT. However, our study indicates that the immune system may be incapable of responding to immunologic manipulation in the immediate post-transplant period.
We have demonstrated that a prolonged period of severe immunologic compromise follows autologous PBSCT, similar to autologous and allogeneic BMT, if a highly myeloablative conditioning chemotherapy regimen is utilized. The clinical effects of this marked immunosuppression include opportunistic viral infections and, possibly, early relapse of breast cancer. We believe that the intensity of myeloablative chemotherapy regimens, such as the one utilized in this study, has been maximized and no significant advances will be forthcoming in this direction. Considerable research is ongoing with immune modulators in the post-transplant setting. 27 However, such an approach is unlikely to be successful because of the marked immunosuppressed state observed shortly after transplantation. If these patients could be reconstituted immunologically, immunotherapy would have more of a chance to be effective. One approach which is currently being studied at our center, is to infuse aliquots of pre-ablative PBMC (T cells, B cells and NK cells) at frequent and defined time intervals during the first 4 months post transplant as a method of adoptive transfer of mature immune cells. It is not yet clear whether such a strategy will help reconstitute these patients more fully and rapidly and decrease the incidence of opportunistic infections and disease relapse. If this method is able to produce rapid reconstitution of the immune system, these patients may become better candidates for immunotherapeutic approaches.
